Pfizer and Biontech have just completed a first interim analysis of their phase 3 trial on a vaccine against the new coronavirus, the last before an application for approval.

In the current state of research, the vaccine is "90% effective", the two laboratories say Monday.

The vaccine against Covid-19 developed by Pfizer and Biontech is "90% effective", the two laboratories say Monday, after the first interim analysis of their phase 3 trial, the last before an application for approval.

This "vaccine efficacy" was measured by comparing the number of participants infected with the novel coronavirus in the group that received the vaccine and in that on placebo, "seven days after the second dose" and 28 days after the first, have- they explained in a joint statement.

>> LIVE -

 Coronavirus: follow the evolution of the situation Monday, November 9

More information to follow.